Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Non-Current Assets (2016 - 2025)

CorMedix's Non-Current Assets history spans 13 years, with the latest figure at $459.1 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 10649.03% year-over-year to $459.1 million; the TTM value through Dec 2025 reached $959.7 million, up 5275.36%, while the annual FY2025 figure was $459.1 million, 10649.03% up from the prior year.
  • Non-Current Assets for Q4 2025 was $459.1 million at CorMedix, down from $491.3 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $491.3 million in Q3 2025 and bottomed at $1.2 million in Q2 2021.
  • The 5-year median for Non-Current Assets is $2.5 million (2021), against an average of $52.7 million.
  • The largest annual shift saw Non-Current Assets decreased 1.9% in 2023 before it surged 10986.07% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $2.5 million in 2021, then increased by 0.42% to $2.5 million in 2022, then fell by 4.84% to $2.4 million in 2023, then skyrocketed by 80.46% to $4.3 million in 2024, then soared by 10649.03% to $459.1 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Non-Current Assets are $459.1 million (Q4 2025), $491.3 million (Q3 2025), and $4.5 million (Q2 2025).